Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003816 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
A Phase 2 study of Lymphoma and Leukemia, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 361
- Enrollment target
- 1
- Study location
NCT00003816 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 361 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00003816, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 361 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known which combination chemotherapy regimen is most effective when given before a donor stem cell transplant in treating aplastic anemia or hematologic cancer. PURPOSE: This phase II/III trial is studying different combination chemotherapy regimens to compare how well they work when given before donor stem cell transplant in treating patients with aplastic anemia or hematologic cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG busulfan
- BIOLOGICAL anti-thymocyte globulin
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 1998-10-19 |
| Est. Completion | 2019-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003816
The ClinicalTrials.gov registry entry for NCT00003816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (25% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which carboplatin is the first listed.
NCT00003816 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00003816 about?
NCT00003816 is a clinical study titled "Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer". RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they m...
What is the current status of trial NCT00003816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 361 participants. The study started on 1998-10-19. Estimated completion is 2019-07-12.
What conditions does trial NCT00003816 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Chronic Myeloproliferative Disorders.
What interventions are being tested in trial NCT00003816?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), busulfan (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003816?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003816 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.